Determination of oxaceprol in rat plasma by LC-MS/MS and its application in a pharmacokinetic study

被引:5
作者
Gu, Jifeng [1 ]
Chen, Nianzu [1 ]
Ding, Guoqiang [2 ]
Zhang, Zhen [1 ]
机构
[1] Fudan Univ, Eye & ENT Hosp, Dept Pharm, Shanghai 200031, Peoples R China
[2] Fudan Univ, Eye & ENT Hosp, Dept Otorhinolaryngol Head & Neck Surg, Shanghai 200031, Peoples R China
关键词
Oxaceprol; LC-MS/MS; Pharmacokinetics; Rat plasma; Oral administration; OSTEOARTHRITIS; DICLOFENAC; THERAPY;
D O I
10.1016/j.jpba.2010.08.011
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A sensitive method for the quantification of oxaceprol in rat plasma using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed. Sample pretreatment involved a simple protein precipitation by the addition of 60 mu L of acetonitrile-methanol (1:2, v/v) to 20 mu L plasma sample volume. Separation was achieved on a Dikma ODS-C18 (5 mu m, 150 mm x 4.6 mm) reversed-phase column at 40 degrees C with acetonitrile/0.1% formic acid-4 mM ammonium acetate in water (35:65,v/v) at a flow rate of 0.6 mL/min. Detection was performed using an electrospray ionization (ESI) operating in negative ion multiple reaction monitoring (MRM) mode by monitoring the ion transitions from m/z 172 -> 130 (oxaceprol) and m/z 153 -> 109 (protocatechuic acid, internal standard). The calibration curve of oxaceprol in plasma showed good linearity over the concentration range of 1.25-800 ng/mL. The limit of detection and limit of quantification were 0.400 ng/mL and 1.25 ng/mL, respectively. Intra- and inter-day precisions in all samples were within 15%. There was no matrix effect. The validated method was successfully applied to a preclinical pharmacokinetic study of oxaceprol in rats. After oral administration of 20 mg/kg oxaceprol to rats, the main pharmacokinetic parameters T(max), C(max), T(1/2), V(z/F) and AUC(0-t) were 1.4 h, 1.2 mu g/mL, 2.3 h, 19.7 L/kg and 3.4 mg h/L, respectively. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:173 / 178
页数:6
相关论文
共 14 条
[1]  
[Anonymous], EXTRACTA ORTHOP
[2]   Oxaceprol is as effective as diclofenac in the therapy of osteoarthritis of the knee and hip [J].
Bauer, HW ;
Klasser, M ;
von Hanstein, KL ;
Rolinger, H ;
Schladitz, G ;
Henke, HD ;
Gimbel, W ;
Steinbach, K .
CLINICAL RHEUMATOLOGY, 1999, 18 (01) :4-9
[3]   A high-throughput LC-MS/MS method for the quantitation of posaconazole in human plasma: Implementing fused core silica liquid chromatography [J].
Cunliffe, Jennifer M. ;
Noren, Carl F. ;
Hayes, Roger N. ;
Clement, Robert P. ;
Shen, Jim X. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2009, 50 (01) :46-52
[4]   Pharmacologic pain treatment of musculoskeletal disorders: Current perspectives and future prospects [J].
Curatolo, M ;
Bogduk, N .
CLINICAL JOURNAL OF PAIN, 2001, 17 (01) :25-32
[5]   Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac [J].
Herrmann, G ;
Steeger, D ;
Klasser, M ;
Wirbitzky, J ;
Fürst, M ;
Venbrocks, R ;
Rohde, H ;
Jungmichel, D ;
Hildebrandt, HD ;
Parnham, MJ ;
Gimbel, W ;
Dirschedl, H .
CLINICAL RHEUMATOLOGY, 2000, 19 (02) :99-104
[6]   Oxaceprol, an atypical inhibitor of inflammation and joint damage. [J].
Ionac, M ;
Parnham, MJ ;
Plauchithiu, M ;
Brune, K .
PHARMACOLOGICAL RESEARCH, 1996, 33 (06) :367-373
[7]  
Juvin E, 1998, SEM HOP PARIS, V74, P47
[8]  
Krüger K, 2007, CLIN EXP RHEUMATOL, V25, P29
[9]  
LACHMANN G, 1990, ARZNEIMITTELFORSCH, V40-1, P200
[10]   Antirheumatic agents and leukocyte recruitment - New light on the mechanism of action of oxaceprol [J].
Parnham, MJ .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (02) :209-215